Type Stock company | Traded as MDG1 Website www.medigene.com | |
Key people Prof Dolores J Schendel (CEO), Dave Lemus (COO), Horst Domdey (Chairman of the supervisory board) Stock price MDG1 (ETR) € 12.39 -0.03 (-0.28%)17 Mar, 9:20 AM GMT+1 - Disclaimer Subsidiaries Munich Biotech AG, MediGene, Inc., Trianta Immunotherapies GmbH Profiles | ||
Are medigene empowering t cells to effectively fight cancer
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
Contents
- Are medigene empowering t cells to effectively fight cancer
- Maydorns meinung tesla daimler deutsche bank bb biotech medigene jinkosolar solaredge
- References
For more information, please visit www.medigene.com
Maydorns meinung tesla daimler deutsche bank bb biotech medigene jinkosolar solaredge
References
MediGene Wikipedia(Text) CC BY-SA